Patents by Inventor Gregory M. Lanza

Gregory M. Lanza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080138288
    Abstract: Long-term treatment of conditions associated with neovasculature is effected by combining targeted acute antiangiogenic agent treatment with chronic treatment with an additional drug.
    Type: Application
    Filed: October 1, 2007
    Publication date: June 12, 2008
    Applicant: Washington University
    Inventors: Gregory M. LANZA, Samuel A. Wickline
  • Patent number: 7344698
    Abstract: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for ?v?3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: March 18, 2008
    Assignees: Barnes-Jewish Hospital, Bristol-Myers Squibb Medical Imaging, Inc.
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Tom Harris
  • Patent number: 7279150
    Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: October 9, 2007
    Assignees: Barnes-Jewish Hospital, The Dow Chemical Corporation
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Phillip S. Athey, Gyongyi Gulyas, Garry E. Kiefer
  • Publication number: 20070232909
    Abstract: Disclosed herein is a technique for performing medical imaging on a region of interest (ROI) wherein information theoretic signal receivers are used to enhance the detection and monitoring of pathologies such as angiogenesis and muscular dystrophy. Examples of information theoretic signal receivers that can be used in the practice of the invention include Shannon entropy signal receivers, continuous limit Shannon entropy signal receivers, Renyi entropy signal receivers, specific heat analog signal receivers, and thermodynamic energy analog signal receivers. The contrast enhancement provided by contrast agents, either targeted contrast agents or bubble-based contrast agents, is enhanced through the use of such information theoretic signal receivers. Further still, the contrast agents can be heated to further enhance visualization with information theoretic signal receivers.
    Type: Application
    Filed: March 28, 2007
    Publication date: October 4, 2007
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Michael S. Hughes, Samuel A. Wickline, Gregory M. Lanza
  • Patent number: 7255875
    Abstract: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for ?v?3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: August 14, 2007
    Assignees: Barnes-Jewish Hospital, Bristol Myers Squibb Medical Imaging, Inc.
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Tom Harris
  • Patent number: 7235227
    Abstract: An improved contrast agent for magnetic resonance imaging comprises particles to each of which is coupled a multiplicity of chelating agents containing paramagnetic ions. In the improved agent, the position of the ion is offset from the surface of the particle so as to improve the relaxivity imparted by the contrast agent. A tether offsetting the chelate from the surface of the particle may optionally contain cleavage sites permitting more facile excretion of the chelated paramagnetic ion.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: June 26, 2007
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Patent number: 7186399
    Abstract: A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance or positron emission tomography. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: March 6, 2007
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Patent number: 7179449
    Abstract: Methods and devices for enhanced ultrasound detection based upon changing temperature and ultrasound reflectivity of a temperature-dependent contrast agent bound to an ultrasound target are disclosed. The methods and devices can be used for enhanced imaging alone or in conjunction with drug delivery, with therapeutic approaches such as hyperthermia or cryotherapy or with other imaging modalities.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: February 20, 2007
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Christopher S. Hall
  • Publication number: 20040248856
    Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.
    Type: Application
    Filed: January 26, 2004
    Publication date: December 9, 2004
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Patent number: 6821506
    Abstract: A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance or positron emission tomography. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: November 23, 2004
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Publication number: 20040115192
    Abstract: A composition for use in delivering a bioactive agent to targeted tissues or cells comprises: (a) a site-specific targeting ligand; (b) a lipid encapsulated oil in water emulsion; and (c) a bioactive agent in or on the surface of the outer monolayer of the emulsion; the ligand being conjugated directly or indirectly to the emulsion and the composition providing facilitated delivery of the bioactive agent through prolonged association and increased contact of the ligand-bound lipid encapsulated emulsion particles with the lipid bilayer of the target tissues or cells. The composition may also comprise a lipid encapsulated oil in water emulsion and a combination site-specific targeting ligand/bioactive agent. Methods for improved delivery of a bioactive agent to targeted tissues or cells are also disclosed.
    Type: Application
    Filed: July 15, 2003
    Publication date: June 17, 2004
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Publication number: 20040058951
    Abstract: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for &agr;v&bgr;3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.
    Type: Application
    Filed: January 24, 2003
    Publication date: March 25, 2004
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Tom Harris
  • Patent number: 6676963
    Abstract: A composition for use in delivering a bioactive agent to targeted tissues or cells comprises: (a) a site-specific targeting ligand; (b) a lipid encapsulated oil in water emulsion; and (c) a bioactive agent in or on the surface of the outer monolayer of the emulsion; the ligand being conjugated directly or indirectly to the emulsion and the composition providing facilitated delivery of the bioactive agent through prolonged association and increased contact of the ligand-bound lipid encapsulated emulsion particles with the lipid bilayer of the target tissues or cells. The composition may also comprise a lipid encapsulated oil in water emulsion and a combination site-specific targeting ligand/bioactive agent. Methods for improved delivery of a bioactive agent to targeted tissues or cells are also disclosed.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: January 13, 2004
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Publication number: 20030215392
    Abstract: An improved contrast agent for magnetic resonance imaging comprises particles to each of which is coupled a multiplicity of chelating agents containing paramagnetic ions. In the improved agent, the position of the ion is offset from the surface of the particle so as to improve the relaxivity imparted by the contrast agent. A tether offsetting the chelate from the surface of the particle may optionally contain cleavage sites permitting more facile excretion of the chelated paramagnetic ion.
    Type: Application
    Filed: March 26, 2003
    Publication date: November 20, 2003
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Publication number: 20030129136
    Abstract: A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance or positron emission tomography. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.
    Type: Application
    Filed: November 22, 2002
    Publication date: July 10, 2003
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Patent number: 6548046
    Abstract: A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site-specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance or positron emission tomography. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: April 15, 2003
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Publication number: 20020168320
    Abstract: A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance or positron emission tomography. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.
    Type: Application
    Filed: December 28, 2001
    Publication date: November 14, 2002
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Publication number: 20020102216
    Abstract: Methods and devices for enhanced ultrasound detection based upon changing temperature and ultrasound reflectivity of a temperature-dependent contrast agent bound to an ultrasound target are disclosed. The methods and devices can be used for enhanced imaging alone or in conjunction with drug delivery, with therapeutic approaches such as hyperthermia or cryotherapy or with other imaging modalities.
    Type: Application
    Filed: January 30, 2001
    Publication date: August 1, 2002
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Christopher S. Hall
  • Patent number: 5989520
    Abstract: A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site-specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance or positron emission tomography. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: November 23, 1999
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline
  • Patent number: 5958371
    Abstract: A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site-specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance, positron emission tomography or nuclear imaging. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: September 28, 1999
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline